Trials / Withdrawn
WithdrawnNCT05518422
Role of Endothelin-1 Modulating Insulin-stimulated Blood Flow and Sympathetic Nervous System Activity in Obesity
- Status
- Withdrawn
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of Missouri-Columbia · Academic / Other
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The aim of this project is to determine role for ET-1 in individuals with obesity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hyperinsulinemic, euglycemic infusion | 60 minute infusion |
Timeline
- Start date
- 2024-02-01
- Primary completion
- 2024-02-01
- Completion
- 2024-02-01
- First posted
- 2022-08-26
- Last updated
- 2024-02-20
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05518422. Inclusion in this directory is not an endorsement.